Michael Farkouh, MD, MSc
Learn more about subscription options.
Register Now for a free account.
Farkouh M. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Ann Intern Med. 2010;152:JC6–10. doi: 10.7326/0003-4819-152-12-201006150-02010
Download citation file:
Published: Ann Intern Med. 2010;152(12):JC6-10.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Prevention/Screening.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only